Effect of the Duration of Pre-oxygenation on Apnea Tolerance in Obese Patients During the Induction of General Anesthesia
OBE_PreOx
1 other identifier
interventional
200
1 country
1
Brief Summary
The occurrence of arterial oxygen desaturation (hypoxemia) during the induction of general anesthesia remains one of the main causes of complications and mortality in anesthesia. In a healthy patient breathing in ambient air \[Inspired O2 fraction (FiO2) = 21%\] before the onset of narcosis, a drop in arterial O2 saturation (SpO2) occurs within 1 to 2 minutes. When pre-oxygenation is performed for 3 minutes in healthy subjects with FiO2 = 100%, SpO2 is less than 97% after 7.9 minutes of apnea and arterial O2 desaturation (SpO2 \<93%) occurs after 8 to 9 minutes. For this reason and "in order to prevent arterial desaturation during tracheal intubation or supraglottic device insertion maneuvers", it is recommended "to systematically perform a pre-oxygenation procedure (3 min / 8 deep breaths) , including in the context of an emergency ". Tolerance to apnea is conditioned by the amount of O2 stored during the pre-oxygenation phase. Oxygen is transported to different tissues in 2 forms: combined with hemoglobin (Hb) and in dissolved form. In ambient air, the quantity of O2 transported by the Hb is much greater than the part transported in dissolved form. However, when the patient breathes a gas enriched in O2, all the molecules of Hb are quickly saturated (SpO2 = 100%), while the content of dissolved O2 increases constituting a reserve allowing to increase the tolerance to apnea. Under usual conditions (3 minutes pre-oxygenation with FiO2 = 1), tolerance to apnea is shorter in obese subjects. Arterial O2 desaturation occurs after 2-3 minutes of apnea in patients with grade III obesity \[Body Mass Index (BMI)\> 35 kg / m2\]. In addition, arterial O2 desaturation is faster the higher the BMI is. In fact, in obese patients, the lung volumes that can be mobilized in the supine position are modified compared to the non-obese subject: decrease in vital capacity, decrease in expiratory reserve volume, increase in airway resistance, decrease in thoracic compliance. These changes are, in part, explained by the weight of tissue on the rib cage and abdomen leading to compression of the lungs and diaphragm. In addition, there is also an increase in oxygen consumption in patients with a BMI\> 40. Different techniques have been proposed to increase apnea tolerance in obese patients. For Dixon et al., The desaturation of the morbidly obese subject (BMI\> 40 kg / m2) is less rapid after 3 minutes of pre-oxygenation carried out with the patient in a half-seated position at 25 °: 201 seconds against 155 seconds in the Control group. This additional time seems to correlate with the value of the arterial pressure in O2 (PaO2) measured at the end of the pre-oxygenation (442 vs 360 mmHg). Likewise, the proclive position (30 ° reverse Trendelenburg) during the pre-oxygenation phase seems effective in limiting the occurrence of desaturation after induction. The O2 reserve is usually assessed by measuring the partial pressure of O2 in the arterial blood. A value greater than 100 mmHg indicates that an amount of O2 is "in reserve", increasing tolerance to apnea. In practice, this examination is not feasible in current practice because it requires the performance of an invasive procedure, cannot be measured continuously and the rendering of the result is delayed by several minutes. In recent years, a technology based on spectrophotometry has been developed to measure the saturation of Hb in O2 in non-pulsatile blood. By algorithmic transformation, an Oxygen Reserve Index (ORI) is calculated. Its value varies from 0 to 1 and covers a data range between 100 and 200 mmHg of blood pressure in O2 (moderate hyperoxia). This data is obtained continuously and non-invasively from a sensor (RD Rainbow SET R Sensors; Masimo) placed on the 3rd or 4th finger of the hand. When a patient receives an O2 enriched gas mixture, the value of ORI increases rapidly and reaches a plateau. When the patient is in apnea, the drop in the ORI value precedes the drop in SpO2 by several tens of seconds. In a pilot study observing the kinetics of ORI in non-obese (BMI \<25 kg / m2) or obese (BMI\> 30 kg / m2) anesthetized patients, we observed that the time required to reach the plateau of l The ORI was longer (133 ± 30 seconds) in "obese" patients compared to "non-obese" patients (89 ± 28 seconds). Thus, one hypothesis to explain the poorer tolerance to apnea in obese patients would be that the duration of 3 minutes of pre-oxygenation as recommended in the recommendations is insufficient.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 30, 2020
CompletedFirst Posted
Study publicly available on registry
January 7, 2021
CompletedStudy Start
First participant enrolled
January 13, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 27, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2024
CompletedApril 14, 2023
April 1, 2023
3.1 years
December 30, 2020
April 13, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Apnea tolerance
This outcome is to compare the duration of apnea tolerance (SpO2 value ≤ 94%) in obese patients (30 kg / m2 \<BMI \<40 kg / m2) depending on the duration of pre-oxygenation (3 minutes vs 6 minutes) during induction of general anesthesia compared to non-obese subjects (BMI \<25 kg / m2).
End of pre-oxygenation 3 min versus 6 min
Secondary Outcomes (1)
ORI profile
End of pre-oxygenation 3 min versus 6 min
Study Arms (3)
Control
EXPERIMENTALPatients with a BMI \<25 kg / m² requiring general anesthesia with a pre-oxygenation for 3 minutes
PreOx_3min
EXPERIMENTALPatients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 3 minutes
PreOx_6min
EXPERIMENTALPatients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 6 minutes
Interventions
All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the "Control" group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded.
Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group "PreOx\_3min". All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the "PreOx\_3min" group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded.
Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group "PreOx\_6min". All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the "PreOx\_3min" group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded.
Eligibility Criteria
You may qualify if:
- Patient aged ≥ 18 years
- Patient to have general anesthesia
- Patient affiliated to a health insurance plan
- French-speaking patient
- Patient who has given free, informed and written consent
You may not qualify if:
- Patient with a BMI between 25 and 30 kg / m2
- Patient with a BMI\> 40 kg / m2
- Patient whose O2 stock is insufficient, without this being linked to obesity
- Patient with severe respiratory pathology (COPD stage 3 or 4, severe asthma)
- Patient with active smoking
- Patient with a history of lobectomy or pneumonectomy
- Patient coming for emergency surgery
- Patient with a known allergy to rocuronium or sufentanil or propofol
- Pregnant or breastfeeding women
- Patient under guardianship or curatorship
- Patient deprived of liberty
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Groupe Hospitalier Paris Saint-Joseph
Paris, Groupe Hospitalier Paris Saint-Joseph, 75014, France
Related Publications (6)
Cook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of airway management in the UK: results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult Airway Society. Part 1: anaesthesia. Br J Anaesth. 2011 May;106(5):617-31. doi: 10.1093/bja/aer058. Epub 2011 Mar 29.
PMID: 21447488RESULTTanoubi I, Drolet P, Donati F. Optimizing preoxygenation in adults. Can J Anaesth. 2009 Jun;56(6):449-66. doi: 10.1007/s12630-009-9084-z. Epub 2009 Apr 28.
PMID: 19399574RESULTGambee AM, Hertzka RE, Fisher DM. Preoxygenation techniques: comparison of three minutes and four breaths. Anesth Analg. 1987 May;66(5):468-70. No abstract available.
PMID: 3578856RESULTJense HG, Dubin SA, Silverstein PI, O'Leary-Escolas U. Effect of obesity on safe duration of apnea in anesthetized humans. Anesth Analg. 1991 Jan;72(1):89-93. doi: 10.1213/00000539-199101000-00016.
PMID: 1984382RESULTBerthoud MC, Peacock JE, Reilly CS. Effectiveness of preoxygenation in morbidly obese patients. Br J Anaesth. 1991 Oct;67(4):464-6. doi: 10.1093/bja/67.4.464.
PMID: 1931404RESULTTsymbal E, Ayala S, Singh A, Applegate RL 2nd, Fleming NW. Study of early warning for desaturation provided by Oxygen Reserve Index in obese patients. J Clin Monit Comput. 2021 Aug;35(4):749-756. doi: 10.1007/s10877-020-00531-w. Epub 2020 May 18.
PMID: 32424516RESULT
Study Officials
- PRINCIPAL INVESTIGATOR
Pascal ALFONSI, MD
Fondation Hôpital Saint-Joseph
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 30, 2020
First Posted
January 7, 2021
Study Start
January 13, 2021
Primary Completion
February 27, 2024
Study Completion
December 30, 2024
Last Updated
April 14, 2023
Record last verified: 2023-04